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Rationale. The diagnosis of pleural malignant mesothelioma (MM) by effusion cytology may be difficult and is currently
controversial. Effusion mesothelin levels are increased in patients with MM but the clinical role of this test is uncertain. Objectives.
To determine the clinical value of measuring mesothelin levels in pleural effusion supernatant to aid diagnosis of MM. Methods
and Measurements. Pleural effusion samples were collected prospectively from 1331 consecutive patients. Mesothelin levels were
determinedbycommercialELISAineffusionsandtheirrelationshiptoconcurrentpathologyreportingandfinalclinicaldiagnosis
wasdetermined.Results.2156pleuraleffusionsamplesfrom1331individualswereanalysed.Thefinalclinicaldiagnosiswas183MM,
436 non-MM malignancy, and 712 nonmalignant effusions. Effusion mesothelin had a sensitivity of 67% for MM at 95% specificity.
Mesothelin was elevated in over 47% of MM cases in effusions obtained before definitive diagnosis of MM was established. In the
settingofinconclusiveeffusioncytology,effusionmesothelinhadapositivepredictivevalueof79%forMMand94%formalignancy.
Conclusions.Amesothelin-positivepleuraleffusion,irrespectiveoftheidentificationofmalignantcells,indicatesthelikelypresence
of malignancy and adds weight to the clinical rationale for further investigation to establish a malignant diagnosis.
1. Introduction
Pleural malignant mesothelioma (MM) is an aggressive
asbestos-induced malignancy. The diagnosis of MM is often
difficult[1]andmaytakeseveralweekstomonthstoestablish
[2]. Current guidelines recommend that a diagnosis be based
ondemonstrationofinvasionbytumorcells[3];however,not
all patients are able to undergo invasive procedures to obtain
a biopsy, and even when tissue is obtained diagnosis may still
be difficult [4]. In MM, patients often present with a pleural
effusionwhichcanbeusedfordiagnosticpurposes.Although
there is controversy regarding the cytological analysis of cells
from pleural effusions, with sensitivities reported in several
studies to be around 30%, the limitation of the technique
relates primarily to difficulty in distinguishing MM from
benign mesothelial cells [3, 5, 6]. However, a high sensitivity
and specificity can be achieved if a standardized approach to
cytodiagnosis is used [7].
In our institution, MM has been diagnosed by effusion
cytologysince1974[7–9]a n dacyt o logicaldia gn osi sfr o ma n
effusion sample in the appropriate clinical context has been
accepted as the basis for patient management, for inclusion
in clinical trials, and also for medicolegal purposes. Indeed
in a recent review of these data, there were no false positive
diagnoses of malignancy reported in the twenty year period
reviewed where the gold standard was histology of biopsy or
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necropsy, together with clinical and radiological follow-up.
Effusion cytology was performed in 63% of MM cases and
demonstrated a positive predictive value of 99% for MM and
100% for malignancy [9].
Pleuraleffusionsmayariseinvariousclinicalsettingsand
identifying the cause of any effusion is important for deter-
mining subsequent treatment. The cause of an effusion can
u s u a l l yb ee s t a b l i s h e db a s e du p o nc l i n i c a lc h a r a c t e r i s t i c si n
association with imaging, biochemical, and microbiological
analysis, together with cytological appearances. Although a
diagnosis of cancer, that is, a malignant effusion, relies upon
pathologicalanalysis,inmanypatientstheindexofsuspicion
is not high enough to indicate the need for thoracoscopic
or other intervention. Biomarkers produced by a suspected
cancer which shed into the local effusion are a logical way to
help guide the decision making of clinicians. This is because
their local production means that levels are higher than in
blood and thus they would be more likely to be an indication
o ft h ep r e s e n c eo fc a n c e rc e l l sl o c a l l ye v e ni ft u m o rc e l l s
are not identified by microscopic examination of the fluid.
Also, biomarkers are easy and quick to measure. Previous
studiesha vesho wntha tsolublemesothelinlevelsineffusions
have a diagnostic accuracy of over 70% [10–16] in MM. The
clinical role for tumor biomarkers in pleural effusions has
not been established so this study undertook to evaluate
the clinical utility of measurement of mesothelin levels in
pleural effusions which are not diagnostic of malignancy in
a large prospectively collected, consecutive series. Analyses
of these data indicate a clinical role for effusion mesothelin
measurements in the diagnostic work-up of patients with
pleural effusions.
2. Materials and Methods
2.1. Samples. Supernatants from pleural effusion samples,
submitted to PathWest Laboratory Medicine (Queen Eliza-
bethIIMedicalCentre,WesternAustralia)between2005and
2010 for cytological analysis for malignancy were collected.
Samples were centrifuged at 1000g for 10min at 4
∘Ca n d
supernatants stored at −80
∘C before analysis. Air dried and
fixed smears and cell blocks were processed for standard
diagnostic cytological assessment, and diagnoses were coded
using the Systematized Nomenclature of Pathology (SNOP)
system [17] by experienced cytopathologists [9]. In a subset
o fs a m p l e sr o u t i n eb i o c h e m i c a la n a l y s e sw e r ep e r f o r m e d
and nonmalignant effusions were classified as exudates or
transuda teso nthebasiso fLigh t ’ scri teria[18].Effusionswere
classified as being associated with an infection if microor-
ganisms were detected in the fluid or if the patient had
concurrent pneumonia. Pathology reports, hospital records,
and the records of the Western Australian MM Registry were
retrospectively interrogated to establish a final diagnosis for
each case. The MM registry evaluates all available data on an
individual, including pathology, radiology, clinical findings,
and asbestos exposure in making a final assessment as to
whether a patient has MM [19]. Variables recorded for analy-
sis included patient demographics, sample date, and SNOP
code. SNOP codes were amalgamated into four categories:
(i) normal, nondiagnostic, or nonmalignant; (ii) containing
atypical cells or being suspicious of malignancy but not
meeting the criteria of malignancy; (iii) malignant excluding
MM; and (iv) MM. Date of diagnosis was recorded as the
date of the first pathology report of malignancy, either based
on effusion or biopsy specimen. This project was approved
by the Sir Charles Gairdner Hospital Human Research Ethics
Committee.
2.2. Quantification of Mesothelin. Soluble mesothelin con-
centrations were determined in duplicate following the man-
ufacturer’sinstructionsusingtheMESOMARKassay(Fujire-
bioDiagnosticsInc.,Malvern,PA)andexpressedinnanomo-
lar (nM). All assays were performed on coded samples by
investigatorswhowereunawareofthepatient’sdiagnosis,and
mesothelin results were not reported to the clinical team at
the request of the Ethics Committee. The limit of detection of
theassaywas0.3nM.Athresholdvalueof20nMwasusedas
the upper limit of normal as previously reported [12].
2.3. Statistical Analysis. Descriptive statistics and receiver
operator characteristic (ROC) curves were performed using
GraphPad Prism for Windows (GraphPad Software, San
Diego, CA). Differences between groups of patients were
assessed by Student’s 𝑡- t e s ta ft e rt r a n s f o r m i n gm e s o t h e l i n
values to the log scale for which the distributions were closer
to normality. For the same reason, median mesothelin values
were estimated from the mean on the log scale and exponen-
tiated to provide the estimate of the median on the original
scale.Differencesbetweenpre-andpostdiagnosismesothelin
levelswereassessedbypaired𝑡-test.Allreported𝑃valuesare
two sided. A level of 𝑃 < 0.05 was accepted as significant.
3. Results
3.1. Subjects. Over the 67-month period of the study 2156
consecutivepleuraleffusionsampleswerecollectedfrom1331
individuals, approximately 40% of whom were female. Data
linkage combined with clinical follow-up revealed that there
were 183 cases of confirmed MM. In over one third of MM
cases (64/183 = 35%) the primary diagnosis was made on
the cytological specimen with clinical and radiological data
supporting the diagnosis. In 99 cases (i.e., 54%) a biopsy
specimen confirmed MM diagnosis. Two cases were diag-
nosed at autopsy and the remaining 18 cases had diagnostic
confirmation following electron microscopic review of the
cytology sample. In summary there were 59 epithelioid, 23
biphasic,and19sarcomatoidMMplusafurther82MMcases
where histological subtype was not specified (Table 1).
There were 436 patients with effusions and non-MM
malignancy,including182casesofprimarylungcancer.There
were 712 cases of effusions in patients without evidence of
malignancy as determined from hospital records until death
or for a median follow-up period of 11 months (range 0–
90 months). Approximately 20% of these benign effusions
were characterised as being transudates although all were
submitted for cytopathological review. There was a higher
ratioofmalestofemalesintheMMgrouprelativetotheother
malignant and benign groups, consistent with the knownDisease Markers 3
Table 1: Final diagnosis, patient characteristics, and mesothelin results.
Final diagnosis 𝑛 Female,
𝑛 (%)
Age,
mean (range)
Mesothelin
1,2
nM
Mesothelin positive
3
𝑛 (%)
MM 183 26 (14%) 71 (45–97) 28 ± 4.3 122 (67%)
Non-MM malignancy all 436 226 (52%) 70 (24–97) 4.7 ± 3.9
∗∗∗ 50 (11%)
Lung cancer 182 78 (43%) 72 (36–97) 5.2 ± 3.6 26 (14%)
Breast cancer 62 61 (98%) 66 (37–96) 4.1 ± 3.3 3 (5%)
Ovarian cancer 11 11 (100%) 64 (42–77) 19 ± 5.1 5 (45%)
Pancreatic cancer 10 2 (20%) 68 (56–77) 6.3 ± 8.4 3 (30%)
Other malignancies 171 74 (44%) 68 (24–94) 3.9 ± 4 13 (8%)
Nonmalignant all 712 260 (37%) 69 (18–99) 3.2 ± 3
∗∗∗ 3 (0.4%)
Transudate 141 58 (41%) 74 (34–99) 3.4 ± 2.7 0 (0%)
Exudate 129 44 (34%) 67 (19–94) 3.4 ± 3.5 2 (2%)
Infection 165 58 (35%) 65 (29–96) 2.3 ± 3.8 1 (0.6%)
Benign—not specified 277 106 (38%) 70 (18–96) 3.5 ± 3.1 0 (0%)
1expontiated mean of log transformed data plus/minus standard error of log transformed data ∗ 100, in the most recent sample received per patient.
2significant difference between indicated cohorts and the mesothelioma cohort as a whole (𝑛 = 183) as determined by Student’s 𝑡-test (
∗∗∗is 𝑃 < 0.0001).
3Number of individuals in whom soluble mesothelin was >20nM in the most recent sample received per patient.
gender imbalance in exposure to the carcinogen, asbestos.
Thedistributionofpatientageswassimilarbetweenthethree
groups (Table 1).
3.2. Pleural Effusion Soluble Mesothelin Concentrations Rel-
ative to Final Diagnosis. In order to determine sensitivity
and specificity of effusion mesothelin for MM and limit
bias in the results, analysis was performed on the most
recent effusion sample received from each individual (𝑛=
1331). Mesothelin concentrations in pleural effusions from
patients with MM (28 ± 4.3nM) were significantly higher
than those from patients with benign effusions (3.2 ± 3nM;
𝑃 < 0.0001) and patients with non-MM malignancies (4.7 ±
3.9nM; 𝑃 < 0.0001)( Table 1; Figure 1). The diagnostic
sensitivity and specificity of pleural effusion mesothelin for
differentiating MM from all other causes of pleural effusion
at a cut-off value of 20nM was 67% (95% CI, 60 to 74%)
and 95% (95% CI, 94 to 96%), respectively. Using ROC
curve analysis, pleural effusion mesothelin generated an area
under the curve (AUC) of 0.877 (95% CI, 0.843 to 0.91)
for differentiating between patients with MM and all other
patientsinthestudy(Figure 2).Takenasagroup,11%ofnon-
MM malignanteffusions were mesothelin positive. Although
absolute numbers were small, patients with primary ovarian
or pancreatic cancers, two tumor types known to express
mesothelinhadrelativelyhigherratesofmesothelinpositivity
than those with other malignancies.
There were 3 out of 712 (i.e., 0.4%) pleural effusions
with mesothelin levels greater than 20nM which were not
associated with malignancy. Two of these three individuals
were female and all were over 77 years of age (clinical
characteristics are presented in Table 2). Two patients are
deceased; one had a history of endometrial malignancy and
no postmortem was performed to exclude the possibility of
pleural malignancy; the second patient underwent necropsy
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Figure1:Solublemesothelinconcentrationsinpleuraleffusion(PE)
supernatants. Results presented for the single, most recent sample
per individual against final clinical diagnosis (𝑛 = 1331). Dashed
horizontallineindicatesupperlimitofnormalthresholdforeffusion
mesothelin (i.e., 20nM).
examination and no pleural malignancy was identified. The
third patient has a relatively short follow-up of 4 months.
3.3. Pleural Effusion Soluble Mesothelin Concentrations Rel-
ative to Cytology Report. In order to compare effusion
mesothelin concentration with cytological diagnosis, pathol-
ogy reports for the most recent sample per individual (𝑛=
1331)werereviewedandrelatedtoeffusionmesothelinlevels.
Approximately 64% of pleural effusions were classified as4 Disease Markers
Table 2: Characteristics of patients with positive effusion mesothelin and no evidence of malignancy.
Mesothelin (nM) Age Sex Condition associated with
effusion and comorbidities
Status Time to follow-up Asbestos exposed Autopsy result
23 85 F Tuberculosis Deceased 4 days Yes ND
34 89 F
Idiopathic
(chronic bronchitis)
Previous history of
endometrial cancer (10
years ago)
Alive 4 months No
28 77 M
Bilateral
bronchopneumonia
pleural plaques
Deceased 13 months Yes No malignancy
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Figure 2: Receiver operating characteristic (ROC) curve showing
accuracy of effusion mesothelin concentrations in the most recent
sample per individual in differentiating all patients with MM (𝑛=
183)f r o ma l lo t h e rc a s e s( 𝑛 = 1148).
nonmalignant, 6% as atypical or suspicious of malignancy,
22% as non-MM malignancy, and 8% as MM. Mesothelin
levels were elevated in 28 of 855 (i.e., 3%) samples reported
as nonmalignant; 24 of 81 (i.e., 30%) atypical or suspicious
samples; 42 of 291 (i.e., 14%) samples reported as non-MM
malignancy;and82of104(i.e.,79%)samplesreportedasMM
(Figure 3).
Of the 855 pleural effusion samples which were classified
as nonmalignant, follow-up was available on 832 (i.e., 97.3%).
There were 167 samples in this group from patients with a
k n o w no rs u b s e q u e n td i a g n o s i so fm a l i g n a n cy ,i n c l u d i n g1 2 4
with non-MM malignancy and 43 with MM (Figure 4). For
thenon-MMcancercases,approximatelyhalfoftheeffusions
were called nondiagnostic because they consisted of blood
only or were not of sufficient sample volume or quality for
a n a l y s i s ,a n dt h er e m a i n i n gh a l fw e r en o t e dt ob ea s s o c i a t e d
with inflammation. Effusion mesothelin level was elevated
in seven of these 124 patients including one patient who
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Figure3:Pleuraleffusionsolublemesothelinconcentrations:results
for single, most recent sample per individual (𝑛 = 1331)p l o t t e d
against the diagnosis reported by cytopathology for that sample.
wasdiagnosedwithmetastaticpancreaticadenocarcinoma14
months after the cytologically-negative/mesothelin-positive
sample (Figure 5(a)).
There were 43 MM cases where the most recently
received effusion sample was reported by the cytologist as
being nondiagnostic or nonmalignant; the majority of these
samples (70%) were noted to contain elevated numbers of
inflammatorycells(Figure 5(b)).Mostoftheseeffusionswere
collected prior to diagnosis or concomitant with diagnosis
madeonamatchingbiopsysample.Effusionmesothelinlevel
was elevated in 19 of these patients including 17 out of 36
(i.e., 47%) before diagnosis made on later biopsy or cytology
sample; two cases were elevated 16 months prior to diagnosis
(Figure 5(b)).
Of the 81 pleural effusion samples which were reported
as being suspicious of malignancy or as containing atypical
cells, 57 were from patients who had an existing diagnosis of
malignancy.Clinicalfollow-uprevealedthatoftheremaining
24 cases, 18 had died with a diagnosis of cancer 7 months
(median and range; 0 to 57 months) after the sample wasDisease Markers 5
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Figure 4: Flow diagram of the study. Number of cases for each category as defined by key (to the left of figure).
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Figure 5: Soluble mesothelin concentrations in pleural effusion supernatants of patients with (a) a final clinical diagnosis of non-MM
malignancy (𝑛 = 124)a n d( b )M M( 𝑛=4 3 ) ,r e l a t i v et ot h et i m eo fd i a g n o s i s .( ×) Effusion samples with cytopathology report of normal
or nondiagnostic; (l) effusion samples reported as being associated with inflammation or containing immune infiltrating cells.
collected, and 6 remained alive 30 months (1 month to 8
years) after the sample was collected with no evidence of
malignancy. Twenty-three effusion samples in this group
werefrompatientswitharecentorpreviousdiagnosisofnon-
MM malignancy, including 8 with metastatic lung cancer
and 4 with metastatic breast cancer. Effusion mesothelin
level was only elevated in one of these samples and this
was from a patient presenting with an effusion containing
atypicalcellsassociatedwithaprimarylungadenocarcinoma
(Figure 6(a)).
Thirty-four effusions from patients with a final diagnosis
of MM were reported as atypical (𝑛=2 6 )o rs u s p i c i o u so f
malignancy (𝑛=8 ), more than two-thirds of which were
from before or near the time of diagnosis. Mesothelin level
was elevated in the effusions of 15 of these 24 (62.5%) pre- or
peridiagnosis samples (Figure 6(b)).
3.4.PositivePredictiveValueofMesothelininEffusionSamples
Not Definitely Diagnosed by Cytology as Malignant. Of the
1331 pleural effusion samples received from each individual,6 Disease Markers
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Figure 6: Soluble mesothelin concentrations in pleural effusion supernatants reported by cytopathology as being atypical (⬦)o rs u s p i c i o u s
of malignancy (X) in patients with a final clinical diagnosis of (a) non-MM malignancy (𝑛=2 3 )a n d( b )M M( 𝑛=3 4 ), relative to the time
of clinical diagnosis.
Table 3: Mesothelin concentrations in effusions nondiagnostic for malignancy by cytology relative to final clinical diagnosis.
Mesothelin Condition Total
MM Non-MM malignancy Nonmalignant Inadequate follow-up
Positive 42 8 3 0 53
Negative 35 139 686 23 883
Total 77 147 689 23 936
PPVMM =4 2 / 5 3=7 9 % .
PPVmalignancy =( 4 2+8 ) / 5 3=9 4 % .
936 were reported as being nondiagnostic, nonmalignant,
atypical, or suspicious of malignancy (i.e., 855 + 81 = 936);
mesothelin level was elevated in 53 (i.e., 5.7%) of these sam-
ples. Clinical follow-up revealed that 42 mesothelin positive
samples were from MM patients, 8 mesothelin positive sam-
plesfrompatientswithothermalignancies,and3frompeople
with no evidence of malignancy on follow-up. Therefore, the
positive predictive value of effusion mesothelin level in effu-
sion samples which were not definitively diagnosed by cytol-
ogy was 79% for MM and 94% for any malignancy (Table 3).
3.5. Pleural Effusions Received from Patients with a Final
Diagnosis of MM. A total of 271 pleural effusion samples
from 183 individuals diagnosed with MM were collected.
The majority of effusion specimens were within 1 month
of the date of clinical diagnosis (mean ± SD; 1.1 ± 7.7
m o n t h s ) .E ff u s i o nm e s o t h e l i nl e v e l sw e r ee l e v a t e di n1 7 0o f
these 271 (63%) samples (Figure 7(a)), including in 8 of the
20 effusions from patients with sarcomatoid MM. Effusion
mesothelin was elevated in 115 of the 174 effusions (66%)
collected before or at the time of diagnosis. In three samples
the mesothelin level was elevated over twelve months before
diagnosis. Furthermore, mesothelin levels were elevated in
43% of samples that were not definitely diagnosed as MM
by cytological assessment (Figure 7(b)). Nearly 80% (82/104)
of effusions reported by cytological diagnosis as MM had
elevated mesothelin levels (Figure 7(b)).
In a subset analysis of 77 cases where an effusion sample
was available before or within one week of a biopsy con-
firming a diagnosis of MM (which included 7 sarcomatoid
and 16 biphasic cases) pleural effusionmesothelinlevels were
elevated in 51 (66%) cases. In the 40 MM cases not reported
as MM by cytology, mesothelin levels were elevated in 11/17
casesreportedasatypicalorsuspicious;6/15ofthosereported
as having an inflammatory infiltrate; and 3/8 nondiagnostic
or negative samples (Figure 7(c)). As expected, the majority,
thatis,60%ofthe51mesothelin-positivecases,werereported
as MM following cytological examination.
4. Discussion
As the diagnosis of pleural MM can be difficult by effusion
cytologyorbiopsyandmaytakeweeksormonthstoestablish,
the use of effusion biomarkers has the potential to aid in
diagnosis and thus to add to clinical decision making. In this
retrospective study we show that elevated mesothelin level in
an effusion is a strong predictive indicator of the presence
of malignancy, particularly MM. Thus effusion mesothelin
level may influence clinical decision making in patients with
effusions.Disease Markers 7
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Figure 7: Pleural effusion soluble mesothelin concentrations in samples received from patients diagnosed with MM. (a) Mesothelin
concentrations plotted relative to the time of diagnosis for MM patients with tumors of different histologies (×) sarcomatoid; (򳵳)b i p h a s i c ;
and (l) epithelial or nonspecified histology. Multiple samples per patient shown (𝑛 = 271). (b) Mesothelin concentrations plotted relative
to the cytopathology report for each specimen. Multiple samples per patient shown (𝑛 = 271). (c) Mesothelin levels in effusions from 77
individuals with a biopsy confirmation of MM diagnosis. The pathology report for samples was (×) normal or nondiagnostic; (l)a s s o c i a t e d
with inflammation or containing immune infiltrating cells; (⬦)a t y p i c a lo rs u s p i c i o u so fm a l i g n a n c yo r( X) MM.
Mesothelin levels have been examined in many series
of serum samples [20]; however problems of confounding
by kidney function [21, 22] and low sensitivity in presymp-
tomatic individuals [23] have limited its acceptance as a
diagnostic marker. In comparison there have been far fewer
studies of the role of mesothelin measurements in pleural
effusions in a diagnostic setting [10–16]. Tumor marker
measurements in effusions have the potential to be more
sensitive than serum measures because proximity of the fluid
to the tumor allows continuous “sampling” of the tumor and
because effusions are derived from an already symptomatic
group.
The data from this study confirm and extend previous
reports in a larger prospectively collected cohort [10, 12]t h a t
mesothelin levels greater than 20nM in effusions are highly
suggestive of malignancy, particularly of MM. With a sensi-
tivity of 67% and specificity of 95% for distinguishing MM
fromallothereffusionsthisstudyconfirmsthatmeasurement
ofmesothelinlevelcontributestothediagnosticinvestigation
of patients with pleural effusions. As 33% of MM cases do
no tha v ea neleva t edmeso thelinlev elthist estisno tsufficien t
fordiagnosticpurposesasastand-alonetest.Thefindingthat
non-MMmesothelinpositivecasesareprimarilyduetoother
malignancies supports the notion that the value of this test
is in differentiating malignant from nonmalignant effusions.
We saw three “false positive” cases, that is, 0.4%; however
only one of these cases underwent postmortem, and one has
relatively short follow-up.
The incidence of MM in this study is relatively high
because Western Australia has one of the highest per capita8 Disease Markers
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Figure8:Suggesteddiagnosticflowchart.Suggestedclinicalroleofeffusionmesothelinestimationinpatientswithpleuraleffusionsinwhom
malignancy, particularly mesothelioma, forms part of the differential diagnosis.
incidence rates of MM in the world, in part because of the
extensive asbestos mining operations conducted in the town
of Wittenoom in the north of the state [24, 25]. Furthermore,
there is a relatively high percentage of MM cases where MM
d i a g n o s i si ss u p p o r t e db ya s s e s s m e n to fc y t o l o g i c a ls a m p l e s .
In this setting nearly 80% of cytologically positive MM
caseshadanelevatedeffusionmesothelinlevel.However,the
finding that mesothelin levels are elevated in 47% of MM
cases in the absence of cytologically identifiable malignant
cells and 62% of cases with atypical or suspicious cells,
highlights the useful role that mesothelin can play in this
setting. Indeed, in centres that lack experience in cytological
diagnosis, the demonstration of elevated mesothelin levels in
an effusion becomes even more important as an indicator of
t h el i k e l yp r e s e n c eo fm a l i g n a n c y ,p a r t i c u l a r l yM M .
The clinical applicability of the test is most evident in
situations where cytology is inconclusive or not routinely
performed as 66% of biopsy-proven MM cases had elevated
mesothelin levels in the effusions before diagnosis, with the
test having a positive predictive value for MM of 79% and
94% for malignancy. Thus, the identification of an elevated
mesothelin level in an effusion warrants further clinical
investigation, which would most likely involve pleuroscopy
withmultiplebiopsies.ThatisinareasofhighMMprevalence
for roughly every five operations performed four MM cases
would be detected; the remaining case still likely to be
malignant. In centres with lower rates of MM, pleuroscopy
of patients with mesothelin positive effusions would be still
worthwhile to identify malignancy of non-MM origin.
One consequence of combining measurement of effusion
mesothelin level and cytopathology is earlier MM diagnosis.
MM may present with nonspecific symptoms and there is
sometimes a long interval of months to years [9] between
presentation and subsequent diagnosis, which may in part
be due to the presence of antecedent symptoms related to
asbestos exposure. In different settings there are varying
levels of suspicion for this cancer. Whilst the measurement
oftumormarkersinpleuraleffusionshasnotbecomeroutine
clinicalpractice[26]theremaybeaclinicaladvantageinMM
diagnosisinhavingapositivediscriminatorytestparticularly
in those centres not experienced in the diagnosis of this
disease and where diagnosis is often complicated and time
consuming. This approach may reduce hospital costs and
the anxiety of waiting for a diagnosis. Further studies will
be required to determine if such earlier diagnosis has any
positive effect on treatment outcomes.
Limitations of this study include that MM cases were not
alldiagnosedbasedonreviewofbiopsyspecimens,indeedin
many of the cases in which histological tissue was examined
this was for treatment reasons (i.e., surgical staging) and
n o tn e c e s s a r i l yf o rd i a g n o s i s .Af u r t h e rc o n f o u n d i n gf a c t o r
with this analysis was the presence of multiple samples per
individual with different reported pathologies, relative to
t h et i m eo fd i a g n o s i s ,r a t h e rt h a nt h i sb e i n gac a s e - c o n t r o l
study. Although compounding the analysis this increases the
applicability of the results to the true clinical situation.
As the clinical utility of the cytological diagnosis of
M Mh a sb e e nc a l l e di n t oq u e s t i o n ,t h ec o n c o m i t a n ta n a l y s i s
of effusion tumour markers including mesothelin, CEA,
Cyfra21-1, and others either alone or in combination may be
a way to improve the clinical uptake of effusion-based MM
diagnosis. This has the advantage of reducing the number of
patients undergoing surgical procedures with the associated
risks and costs.
Given these data and acknowledging that the pretest
probability of different malignancies varies between centres,
we recommend the following general diagnostic approach to
the analysis of effusion samples that are sent for cytological
analysis (Figure 8).Firstly,ifthecytologicalanalysisprovides
sufficient information to establish the diagnosis of cancer,
analysis of effusion mesothelin levels does not add any-
thing. Secondly, if the cytological analysis is nondiagnostic
or negative for malignancy, then effusion mesothelin level
should be measured as the positive predictive value of the
test for malignancy is high. What then happens will depend
upon clinical circumstances, but if an elevated mesothelin
level is detected the patient would typically undergo further
imaging and thoracoscopic examination and biopsy. Thus,
currently, patients in whom such an intervention might not
otherwisebeundertakenwouldundergothoracoscopy.ThereDisease Markers 9
arecaseswhereanondiagnosticeffusionsamplewouldnotbe
followed up by a thoracoscopy. An elevated mesothelin level,
when there is a low index of suspicion of malignancy, would
increasethelevelofsuspicion.Finally,ifthecytologicalanaly-
sis shows atypical or suspicious cells, measurement of pleural
fluidmesothelinmightbesufficienttosupportthecytological
diagnosis and will expedite further clinical decision making,
especially regarding thoracoscopy and biopsy.
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